The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 29, 2024 and March 31, 2023 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.


	Biotechnology		Life Sciences		Diagnostics		Total
For the Three-Month Period Ended March 29, 2024:
Geographical region:
North America(a)	$	514	$	781	$	1,337	$	2,632
Western Europe	546		372		406		1,324
Other developed markets(b)	79		125		99		303
High-growth markets(c)	385		467		685		1,537
Total	$	1,524	$	1,745	$	2,527	$	5,796

Revenue type:
Recurring	$	1,309	$	1,192	$	2,294	$	4,795
Nonrecurring	215		553		233		1,001
Total	$	1,524	$	1,745	$	2,527	$	5,796

For the Three-Month Period Ended March 31, 2023:
Geographical region:
North America(a)	$	618	$	708	$	1,124	$	2,450
Western Europe	647		364		420		1,431
Other developed markets(b)	79		128		117		324
High-growth markets(c)	520		509		715		1,744
Total	$	1,864	$	1,709	$	2,376	$	5,949

Revenue type:
Recurring	$	1,511	$	1,039	$	2,112	$	4,662
Nonrecurring	353		670		264		1,287
Total	$	1,864	$	1,709	$	2,376	$	5,949

(c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.